Treatment and Prevention of Shingles (Herpes Zoster)
For acute shingles, start oral antiviral therapy within 72 hours of rash onset with valacyclovir 1g three times daily, famciclovir 500mg three times daily, or acyclovir 800mg five times daily for 7 days, and manage pain aggressively to prevent postherpetic neuralgia.
Acute Treatment
Antiviral Therapy
The cornerstone of shingles management is prompt antiviral treatment. Initiate therapy within 72 hours of rash appearance to reduce disease duration, severity of acute pain, and risk of postherpetic neuralgia 1, 2, 3. The standard regimens are:
- Valacyclovir 1g orally three times daily for 7 days (preferred due to better bioavailability)
- Famciclovir 500mg orally three times daily for 7 days
- Acyclovir 800mg orally five times daily for 7 days
All three agents demonstrate comparable clinical efficacy 1, 2. Valacyclovir and famciclovir offer more convenient dosing schedules, which may improve adherence. For severe or disseminated disease, particularly in immunocompromised patients, use intravenous acyclovir 3.
Critical timing caveat: While the 72-hour window is emphasized, patients presenting beyond this timeframe who have new vesicle formation, complications, or are immunocompromised should still receive antivirals 1.
Pain Management
Aggressive pain control during acute infection reduces the risk of postherpetic neuralgia 4, 1. Use a multimodal approach:
- Acetaminophen or NSAIDs for mild-to-moderate pain
- Opioids for severe acute pain (short-term use)
- Gabapentinoids (gabapentin or pregabalin) started early may reduce progression to postherpetic neuralgia
- Topical lidocaine for localized pain relief
Local Care
Keep lesions clean and dry. Avoid topical antibiotics unless secondary bacterial infection develops 1.
Prevention: Vaccination
Recombinant Zoster Vaccine (RZV, Shingrix)
RZV is the vaccine of choice for all eligible adults due to superior efficacy compared to the older live attenuated vaccine 5, 4, 6.
Recommended populations:
- All adults ≥50 years old: Two doses given 2-6 months apart 4, 2
- Adults ≥18 years who are or will be immunocompromised: Two doses regardless of prior varicella or shingles history 6
Key advantages of RZV:
- 90-97% efficacy in preventing shingles 4
- Can be used in immunocompromised patients (unlike live vaccine) 6
- Protection remains high even in adults ≥70 years 5
Important vaccination points:
- Administer even if patient had prior shingles (wait at least 1 year after acute episode) 2
- Give regardless of prior varicella vaccination or chickenpox history 5
- Both doses are necessary for optimal protection 4
Common pitfall: Vaccine adverse effects (injection site pain, myalgia, fatigue) occur in 50-70% of recipients but are temporary 4. Counsel patients preemptively to prevent dose abandonment.
Postherpetic Neuralgia Management
If pain persists >90 days after rash onset, diagnose postherpetic neuralgia, which affects 10-18% of shingles patients 4, 2.
First-line treatments:
- Gabapentin (300-3600mg daily in divided doses) or pregabalin (150-600mg daily)
- Duloxetine or other serotonin-norepinephrine reuptake inhibitors
- Tricyclic antidepressants (amitriptyline, nortriptyline)
Adjunctive topical therapy:
- Lidocaine patches 5% applied to affected area
- Capsaicin cream 8% (high-concentration formulation)
These agents can be combined for refractory cases 4, 1, 2.
Special Populations
Immunocompromised Patients
- Higher risk of disseminated disease and complications 7, 6
- Consider intravenous acyclovir for severe cases 3
- RZV vaccination is safe and strongly recommended for those ≥18 years with immunocompromise 6
- For acyclovir-resistant cases (rare), use foscarnet 8, 7
HIV-Infected Patients
- Shingles incidence is 15-fold higher than general population 7
- Standard oral antivirals effective at any CD4 count 8
- Daily suppressive acyclovir or famciclovir for frequent recurrences 8
Pregnant Women
- Acyclovir is safe during pregnancy 8
- Treat acute shingles with standard acyclovir regimens
Key Clinical Pearls
Do not delay treatment waiting for laboratory confirmation—diagnosis is clinical based on dermatomal vesicular rash 9, 1.
Red flags requiring immediate evaluation:
- Ophthalmic involvement (rash on tip of nose—Hutchinson's sign)
- Disseminated rash (>20 lesions outside primary dermatome)
- Immunocompromised status
- Neurological symptoms suggesting meningitis or encephalitis
Vaccination is cost-effective and dramatically reduces disease burden, particularly in high-risk populations 5, 6. The primary barrier is awareness—actively recommend RZV to all eligible patients.